# US 10,865,239 B2 · Treatment of fibrosis with interleukin-11 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,865,239 B2
- Document ID: US10865239B2
- Status: Granted
- Kind: B2
- Application number: 16/055,261
- Filed: 2018-08-06
- Published: 2018-12-20
- Granted: 2020-12-15
- Earliest claimed: 2015-12-16
- Assignees: Singapore Health Services Pte Ltd; National University of Singapore
- Applicants: Singapore Health Services PTE LTD.; National University of Singapore
- Inventors: Stuart Alexander Cook; Sebastian Schaefer
- Web page: https://patentgrep.com/patent/US10865239B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/5428: {IL-10}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/43: containing a FLAG-tag
- C12N 2310/14: interfering nucleic acids [NA]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

## Claims

### Claim 1

A method of treating a disease or condition characterised by fibrosis of an organ of the gastrointestinal system in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease or condition is characterised by fibrosis of the intestine, small intestine, large intestine, liver, or pancreas.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the disease or condition is selected from the group consisting of Crohn's disease, microscopic colitis, and primary sclerosing cholangitis (PSC).

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.

### Claim 8 (depends on 2)

The method of claim 2, wherein the intestine is the small intestine or the large intestine.

### Claim 9

A method of treating a disease or condition characterised by fibrosis selected from the group consisting of Crohn's disease, microscopic colitis, and primary sclerosing cholangitis (PSC) in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.

### Claim 10 (depends on 9)

The method according to any claim 9, wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.

### Claim 11 (depends on 9)

The method according to any claim 9, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.

### Claim 12 (depends on 9)

The method according to any claim 9, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.

### Claim 13 (depends on 9)

The method according to any claim 9, wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.